A Modified Variant of Fasciola hepatica FhSAP-2 (mFhSAP-2) as a Recombinant Vaccine Candidate Induces High-Avidity IgG2c Antibodies and Enhances T Cell Activation in C57BL/6 Mice
Our results demonstrate that mFhSAP-2 retained its immunogenicity and Th1-polarizing properties, which were enhanced by the Montanide ISA50 adjuvant. The present study highlights the feasibility of inducing Th1-associated immune responses in mice using mFhSAP-2 as an antigen. Further studies are required to assess the potential application of the mFhSAP-2+ISA50 formulation as a vaccine against <i>F. hepatica</i> in natural hosts such as cattle and sheep, which could contribute to improved control and aid in the prevention and eradication of <i>F. hepatica</i> infection.
Authors
- Ana M. Espino (ORCID: https://orcid.org/0000-0001-8456-2550)
- Carlimar Ocasio‐Malavé
- Albersy Armina-Rodríguez (ORCID: https://orcid.org/0000-0002-7126-2804)
- María Del Mar Figueroa-Gispert (ORCID: https://orcid.org/0000-0002-7565-0193)
- Riseilly Ramos-Nieves
- Ghalib Figueroa-Quiñones (ORCID: https://orcid.org/0009-0003-1659-1028)
Institutions
- University of Puerto Rico, Medical Sciences Campus (PR)
- University of Puerto Rico at Arecibo (PR)
Publication Details
- Journal
- Vaccines
- Published
- 2025-05-20
- DOI
- https://doi.org/10.3390/vaccines13050545
- Primary Topic
- Helminth infection and control
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases